OT
Outlook Therapeutics, Inc.
OTLK · NASDAQ
$0.68 -2.04% (-$0.01)
1M -1.32%
Market Cap $127.3M
P/E Ratio -
Div. Yield -
ROE -
Bulios Fair Price
$0.78
14.5% upside
Current Price
$0.68
Undervalued Fair Value Overvalued
According to Bulios Fair Price, OTLK is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
4/9Valuation
100 /100
Cheap P/S -109.48x
P/E N/A
P/FFO N/A
Growth
-
N/A EPS growth N/A
Book val. growth N/A
Rev. growth N/A
Profitability
100 /100
Strong Gross margin 195.64%
FCF margin 3,763,620,000.00%
Net margin 5,254.81%
Quality
2 /100
Poor ROIC 0.00%
Asset turnover -0.00x
ROA 0.00%
Debt
0 /100
High Current ratio 0.00x
Int. coverage -236.12x
Debt/Equity N/A
Stability
72 /100
Stable Beta 0.75x
Profitable years 0
EPS volatility 21.86%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about OTLK
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Robert Charles Jahr
Employees
17
Headquarters
Iselin
Upcoming events
18 DEC
Earnings
Upcoming earnings report